Cardior Pharmaceuticals GmbH
- Address
- Hollerithallee 20, Marienwerder
Sponsor Overview
Specializations
Cardiovascular medicine
Research activity is centered on acute myocardial infarction and subsequent left-sided heart failure, with attention to patients who develop reduced left ventricular ejection fraction after STEMI or NSTEMI.
- Post-infarction cardiac dysfunction
- Left ventricular impairment
- Heart failure after myocardial injury
The clinical focus reflects interest in conditions where myocardial damage leads to persistent ventricular dysfunction and symptomatic cardiac insufficiency.
Heart failure therapeutics
The sponsor is involved in therapeutic development for heart failure management in the setting of reduced pump function, with emphasis on add-on treatment alongside standard of care.
- Reduced ejection fraction heart failure
- Adjunctive cardiac therapy
- Symptomatic ventricular dysfunction
This area highlights a focus on interventions intended to address ongoing myocardial and ventricular abnormalities after an ischemic event.
Ischemic heart disease
Clinical interest extends to the aftermath of ischemic cardiac events, particularly the transition from acute coronary injury to chronic structural and functional heart damage.
- Myocardial ischemic injury
- Cardiac remodeling
- Coronary event sequelae
The research landscape is aligned with therapies targeting the persistent consequences of coronary occlusion and reperfusion-related injury.
Cardiac RNA-based therapy
The funded program includes interest in oligonucleotide-based approaches for cardiovascular disease, reflecting work in molecularly targeted treatment of post-infarction cardiac dysfunction.
- RNA-targeted therapeutics
- Molecular cardiology
- Targeted myocardial intervention
This therapeutic domain connects precision molecular intervention with the treatment of structural and functional heart disease.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety Evaluation of CDR132L in Patients with Post-Myocardial Infarction Reduced Left Ventricular Ejection Fraction: A Phase 2 Randomized Controlled Trial |  Czechia Germany Greece Hungary Poland Spain The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 2 are not being studied by other sponsors.
This sponsor has worked with 47 sites across their trial portfolio.
Therapeutic Focus
- 1.Cardiovascular Diseases1 trial359 other sponsors
Partnered Research Centres
47 centres- Address
- Ul. Aleje Raclawickie 23, 20-049 Lublin
- Address
- Ul. Rudolfa Weigla 5, 53-114 Wroclaw
- Address
- Vassilissis Sofias Avenue 80, 115 28 Athens
- Address
- Ul. Franklina Delano Roosevelta 2, 47-200 Kedzierzyn-Kozle
- Address
- Estrada Clara Campoamor N 341, 36312 Vigo
- Address
- Jaszai Mari Utca 3, 7623 Pécs
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Cardior Pharmaceuticals GmbH.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.